Intranasal stem cell therapy may one day treat brain disorders
Many diseases of the central nervous system involve the death of neurons—so, theoretically, the replacement of dead cells should improve symptoms of degenerative disorders such as Parkinson’s, Huntington’s, amyotrophic lateral sclerosis (ALS) and Alzheimer’s, as well as stroke and brain tumors. Stem cell therapy may do just that even though evidence of its effectiveness is mixed.
In any cell transplant procedure, the host organ—in this case, the brain—may reject its new additions. Further, it is unclear whether grafted cells can truly integrate into complex neural circuitry. Finally, current procedures require invasive surgical implantation, which can be expensive and risky. The surgery can cause neural inflammation, and the implanted cells may quickly die.
Intranasal administration may address at least some of these issues. Most important, it eliminates the need for surgery. Further, some research suggests that stem cells delivered intranasally are “smart”—they do not spread through the brain indiscriminately but instead target damaged cells.
The Latest on: Intranasal stem cell therapy
[google_news title=”” keyword=”Intranasal stem cell therapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Intranasal stem cell therapy
- Preclinical study finds novel stem cell therapy boosts neural repair after cardiac arreston May 1, 2024 at 10:13 am
Researchers at the University of Maryland School of Medicine (UMSOM) have identified an innovation in stem cell therapy to regenerate neural cells in the brain after cardiac arrest in an animal model.
- 46% of Americans have seasonal allergies — and 22% have missed work or school because of it, new Yahoo/YouGov poll findson April 29, 2024 at 2:35 pm
If allergy symptoms are bothersome or impact quality of life, experts say it’s time to take medications. Here's what experts recommend.
- TNXP: Approval of First New Fibromyalgia Drug in 15 Years Possible in 2025…on April 29, 2024 at 8:31 am
TNXP READ THE FULL TNXP RESEARCH REPORT Business Update NDA Filing in 2H24; Pre-NDA Meeting in 2Q24 In the second half of 2024, Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) will be filing a new ...
- Common antibiotic Neosporin may shield against viral respiratory infectionson April 26, 2024 at 9:00 am
A study conducted first in mice and then in human volunteers suggests that a common antibiotic, neomycin, which is the main active ingredient in Neosporin, may help protect against viral respiratory ...
- CD7 CAR T-Cell Therapy, Stem-Cell Transplant Beneficial for CD7-Positive Tumorson April 25, 2024 at 11:30 pm
For patients with relapsed or refractory CD7-positive leukemia or lymphoma, sequential CD7 chimeric antigen receptor (CAR) T-cell therapy followed by haploidentical hematopoietic stem-cell ...
- Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumabon April 25, 2024 at 9:00 am
*EA5 showed a worsening in their White Matter Z-Score at three months during a pseudo-exacerbation of the patient’s trigeminal neuralgia.
- New device improves stem cell generation and chance for accessible Alzheimer's cell therapyon April 24, 2024 at 12:11 pm
Researchers in Sweden say they have improved on a technique for converting regular skin cells into neural stem cells—an advance that they say helps close the gap for accessible personalized cell-based ...
- LSU researchers develop syringe device for enhanced stem cell therapyon April 24, 2024 at 6:00 am
LSU researchers led by veterinary medicine professor Mandi Lopez have introduced a groundbreaking syringe device that could revolutionize tendon injury treatment.
- Foralumab found to ease fatigue in SPMS patients in access programon April 23, 2024 at 10:00 pm
Use of foralumab nasal spray was found to reduce fatigue levels in seven of 10 patients with nonactive SPMS in an expanded access program.
- Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Programon April 22, 2024 at 4:12 am
All Patients Have Either Stabilized or Improved on Nasal Foralumab Treatment and No Patients Declined in Key Clinical Measures NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd.
via Bing News
